JP2014506877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506877A5 JP2014506877A5 JP2013547843A JP2013547843A JP2014506877A5 JP 2014506877 A5 JP2014506877 A5 JP 2014506877A5 JP 2013547843 A JP2013547843 A JP 2013547843A JP 2013547843 A JP2013547843 A JP 2013547843A JP 2014506877 A5 JP2014506877 A5 JP 2014506877A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- amide
- indol
- carbamoyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, amino Chemical group 0.000 claims 580
- 229910052739 hydrogen Inorganic materials 0.000 claims 109
- 239000001257 hydrogen Substances 0.000 claims 90
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 85
- SLJSRCNCQDNSEY-IMJSIDKUSA-N (2s,4s)-4-aminopyrrolidine-1,2-dicarboxylic acid Chemical compound N[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 SLJSRCNCQDNSEY-IMJSIDKUSA-N 0.000 claims 71
- LYKWZKBLNOCJMA-UHFFFAOYSA-N (3-chloro-2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1F LYKWZKBLNOCJMA-UHFFFAOYSA-N 0.000 claims 69
- 150000002431 hydrogen Chemical class 0.000 claims 67
- 229910052736 halogen Inorganic materials 0.000 claims 66
- GXFAYZBQUMULJS-DMTCNVIQSA-N (2s,4r)-4-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@@H](F)CN1C(O)=O GXFAYZBQUMULJS-DMTCNVIQSA-N 0.000 claims 65
- 150000002367 halogens Chemical class 0.000 claims 65
- XEAZDLMCKFROGX-WDCZJNDASA-N (1r,3s,5r)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound OC(=O)N1[C@H](C(=O)O)C[C@H]2C[C@H]21 XEAZDLMCKFROGX-WDCZJNDASA-N 0.000 claims 59
- 125000001424 substituent group Chemical group 0.000 claims 45
- 125000005843 halogen group Chemical group 0.000 claims 44
- 229910052799 carbon Inorganic materials 0.000 claims 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 37
- 229910052760 oxygen Inorganic materials 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 229910052757 nitrogen Inorganic materials 0.000 claims 25
- 229910052717 sulfur Inorganic materials 0.000 claims 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000001153 fluoro group Chemical group F* 0.000 claims 20
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 20
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 19
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 16
- UVSHQGAAWFMJDK-VKHMYHEASA-N (2S)-1,3-thiazolidine-2,3-dicarboxylic acid Chemical compound OC(=O)[C@@H]1SCCN1C(O)=O UVSHQGAAWFMJDK-VKHMYHEASA-N 0.000 claims 15
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 15
- 150000001408 amides Chemical class 0.000 claims 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 14
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 claims 13
- 125000006413 ring segment Chemical group 0.000 claims 13
- 150000003536 tetrazoles Chemical class 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 12
- 150000001204 N-oxides Chemical class 0.000 claims 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 10
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 125000004434 sulfur atom Chemical group 0.000 claims 10
- 150000001721 carbon Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- LCJSRFXMMUVIJO-LYRGGWFBSA-N (1r,3s,5r)-2-[2-(3-acetylindol-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)C)=CN1CC(=O)N1[C@H](C(O)=O)C[C@H]2C[C@H]21 LCJSRFXMMUVIJO-LYRGGWFBSA-N 0.000 claims 6
- AWXDDXPSAPKTTK-DMTCNVIQSA-N (2s,3r)-3-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound O[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O AWXDDXPSAPKTTK-DMTCNVIQSA-N 0.000 claims 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000005711 Benzoic acid Substances 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- ZXNDWVDSVLPGNK-YUPRTTJUSA-N (1s,2s,5r)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound C1N(C(O)=O)[C@H](C(=O)O)[C@H]2C[C@H]21 ZXNDWVDSVLPGNK-YUPRTTJUSA-N 0.000 claims 5
- UHTCLRWCFCIEDS-FFWSUHOLSA-N (2S,4S)-4-(aminomethyl)-4-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound NC[C@@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 UHTCLRWCFCIEDS-FFWSUHOLSA-N 0.000 claims 5
- FJKLVSCNTJZZLB-MHTLYPKNSA-N (2s,4r)-4-fluoro-4-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound C[C@@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 FJKLVSCNTJZZLB-MHTLYPKNSA-N 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 5
- ZXNDWVDSVLPGNK-WDCZJNDASA-N (1r,2s,5s)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound C1N(C(O)=O)[C@H](C(=O)O)[C@@H]2C[C@@H]21 ZXNDWVDSVLPGNK-WDCZJNDASA-N 0.000 claims 4
- OHZUCDHZOHSBPZ-UHFFFAOYSA-N (2,3-difluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1F OHZUCDHZOHSBPZ-UHFFFAOYSA-N 0.000 claims 4
- QMZKFOSMBYTKSY-WHFBIAKZSA-N (2S,4S)-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 QMZKFOSMBYTKSY-WHFBIAKZSA-N 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 4
- ZCJAYDKWZAWMPR-UHFFFAOYSA-N 1-chloro-2-fluorobenzene Chemical compound FC1=CC=CC=C1Cl ZCJAYDKWZAWMPR-UHFFFAOYSA-N 0.000 claims 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 4
- 241000051616 Ulmus minor Species 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000004702 methyl esters Chemical class 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- HIOKSLZQCATFPU-UUEMRFSQSA-N (1R,3S,5S)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound C([C@H](N1C(O)=O)C(O)=O)[C@]2(CO)[C@H]1C2 HIOKSLZQCATFPU-UUEMRFSQSA-N 0.000 claims 3
- SVEKDOPPNJXIJM-DMTCNVIQSA-N (2s,3r)-3-aminopyrrolidine-1,2-dicarboxylic acid Chemical compound N[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O SVEKDOPPNJXIJM-DMTCNVIQSA-N 0.000 claims 3
- JHMMSHOPBJYVAA-RRQGHBQHSA-N (2s,3s,4s)-1-[2-(3-acetylindol-1-yl)acetyl]-4-fluoro-3-methoxypyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1[C@H](OC)[C@@H](F)CN1C(=O)CN1C2=CC=CC=C2C(C(C)=O)=C1 JHMMSHOPBJYVAA-RRQGHBQHSA-N 0.000 claims 3
- LSMBIAVEACWSEH-YGRLFVJLSA-N (2s,4r)-4-fluoro-1-[2-[3-(2-hydroxyacetyl)indol-1-yl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C12=CC=CC=C2C(C(=O)CO)=CN1CC(=O)N1C[C@H](F)C[C@H]1C(O)=O LSMBIAVEACWSEH-YGRLFVJLSA-N 0.000 claims 3
- VKKBGPPYRLLFIL-UHFFFAOYSA-N (3-chloro-2,6-difluorophenyl)methanamine Chemical compound NCC1=C(F)C=CC(Cl)=C1F VKKBGPPYRLLFIL-UHFFFAOYSA-N 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 claims 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical compound ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 230000024203 complement activation Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 125000003700 epoxy group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 229940095102 methyl benzoate Drugs 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- VCARPLHUPPGQJK-UHFFFAOYSA-N n-azidohydroxylamine Chemical group ONN=[N+]=[N-] VCARPLHUPPGQJK-UHFFFAOYSA-N 0.000 claims 3
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- WTWXLOUOFOXIFQ-MYINAIGISA-N (1R,3S,5S)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound C([C@H](N1C(O)=O)C(O)=O)[C@]2(COC)[C@H]1C2 WTWXLOUOFOXIFQ-MYINAIGISA-N 0.000 claims 2
- WXBIYUHOPUIBHC-FBCQKBJTSA-N (1s,5r)-2-azabicyclo[3.1.0]hexane-1,2-dicarboxylic acid Chemical compound OC(=O)N1CC[C@@H]2C[C@]12C(O)=O WXBIYUHOPUIBHC-FBCQKBJTSA-N 0.000 claims 2
- LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 claims 2
- NMXRFBXFBFIUOM-DMTCNVIQSA-N (2R,3R)-3-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1[C@H](F)CCN1C(O)=O NMXRFBXFBFIUOM-DMTCNVIQSA-N 0.000 claims 2
- NMXRFBXFBFIUOM-IMJSIDKUSA-N (2R,3S)-3-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1[C@@H](F)CCN1C(O)=O NMXRFBXFBFIUOM-IMJSIDKUSA-N 0.000 claims 2
- BSDTWIGMXYKJEV-NUNKFHFFSA-N (2S,3S,4S)-3-amino-4-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound N[C@@H]1[C@@H](F)CN(C(O)=O)[C@@H]1C(O)=O BSDTWIGMXYKJEV-NUNKFHFFSA-N 0.000 claims 2
- IYOXBCOLEAZKBF-VKHMYHEASA-N (2s)-4,4-difluoropyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CC(F)(F)CN1C(O)=O IYOXBCOLEAZKBF-VKHMYHEASA-N 0.000 claims 2
- SMCWNPAVVQIDBM-YFKPBYRVSA-N (2s)-piperidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C(O)=O SMCWNPAVVQIDBM-YFKPBYRVSA-N 0.000 claims 2
- BUPZCXUOXVKTKF-VAYJURFESA-N (2s,3s,4s)-4-fluoro-3-methoxypyrrolidine-1,2-dicarboxylic acid Chemical compound CO[C@@H]1[C@@H](F)CN(C(O)=O)[C@@H]1C(O)=O BUPZCXUOXVKTKF-VAYJURFESA-N 0.000 claims 2
- JCINQOYGBLWVGB-UHNVWZDZSA-N (2s,4s)-4-cyanopyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H](C#N)CN1C(O)=O JCINQOYGBLWVGB-UHNVWZDZSA-N 0.000 claims 2
- HHDQVBSXYDRQGD-IMJSIDKUSA-N (2s,4s)-4-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound O[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 HHDQVBSXYDRQGD-IMJSIDKUSA-N 0.000 claims 2
- FCKBTVFCMVATOG-RITPCOANSA-N (2s,5r)-5-ethylpyrrolidine-1,2-dicarboxylic acid Chemical compound CC[C@@H]1CC[C@@H](C(O)=O)N1C(O)=O FCKBTVFCMVATOG-RITPCOANSA-N 0.000 claims 2
- PDXRPVFVFWBERR-UHNVWZDZSA-N (2s,5r)-5-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound C[C@@H]1CC[C@@H](C(O)=O)N1C(O)=O PDXRPVFVFWBERR-UHNVWZDZSA-N 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- UQPXYEYBUROSJF-UHFFFAOYSA-N 1,6-diazaspiro[3.3]heptane Chemical compound N1CCC11CNC1 UQPXYEYBUROSJF-UHFFFAOYSA-N 0.000 claims 2
- ZWLWJCWOPCLRKQ-UHFFFAOYSA-N 1-hydroxytetrazole-5-carbonitrile Chemical compound ON1N=NN=C1C#N ZWLWJCWOPCLRKQ-UHFFFAOYSA-N 0.000 claims 2
- ZPJGOWOMUISLPL-UHFFFAOYSA-N 1-oxa-6-azaspiro[3.3]heptane Chemical compound O1CCC11CNC1 ZPJGOWOMUISLPL-UHFFFAOYSA-N 0.000 claims 2
- JXBKZAYVMSNKHA-UHFFFAOYSA-N 1h-tetrazol-1-ium-5-olate Chemical compound OC=1N=NNN=1 JXBKZAYVMSNKHA-UHFFFAOYSA-N 0.000 claims 2
- OTVAEFIXJLOWRX-UHFFFAOYSA-N 2,2-dichloro-n-[1,3-dihydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide Chemical group CS(=O)(=O)C1=CC=C(C(O)C(CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-UHFFFAOYSA-N 0.000 claims 2
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 claims 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- PSEFWMGUIGBSMX-UHFFFAOYSA-N 3,4-dihydropyrazole-2,3-dicarboxylic acid Chemical compound OC(=O)C1CC=NN1C(O)=O PSEFWMGUIGBSMX-UHFFFAOYSA-N 0.000 claims 2
- JNZYADHPGVZMQK-UHFFFAOYSA-N 3-(aminomethyl)phenol Chemical compound NCC1=CC=CC(O)=C1 JNZYADHPGVZMQK-UHFFFAOYSA-N 0.000 claims 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- IPQLKFAHUWJGQR-UHNVWZDZSA-N NC[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 Chemical compound NC[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 IPQLKFAHUWJGQR-UHNVWZDZSA-N 0.000 claims 2
- SVEKDOPPNJXIJM-IMJSIDKUSA-N N[C@H]1CCN(C(O)=O)[C@@H]1C(O)=O Chemical compound N[C@H]1CCN(C(O)=O)[C@@H]1C(O)=O SVEKDOPPNJXIJM-IMJSIDKUSA-N 0.000 claims 2
- BWOJKKSOJQRQGD-RNCFNFMXSA-N OC(=O)[C@@H]1C[C@@H](F)CN1C(=O)Cn1cc(C(=O)C(F)(F)F)c2ccccc12 Chemical compound OC(=O)[C@@H]1C[C@@H](F)CN1C(=O)Cn1cc(C(=O)C(F)(F)F)c2ccccc12 BWOJKKSOJQRQGD-RNCFNFMXSA-N 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- WTWXLOUOFOXIFQ-ATVXKPNKSA-N (1S,3S,5R)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound C([C@H](N1C(O)=O)C(O)=O)[C@@]2(COC)[C@@H]1C2 WTWXLOUOFOXIFQ-ATVXKPNKSA-N 0.000 claims 1
- PSHYTLBRFRTYSP-JLDZCNIISA-N (1r,2s,5s)-3-[2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound O=C([C@@H]1[C@@H]2C[C@@H]2CN1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F PSHYTLBRFRTYSP-JLDZCNIISA-N 0.000 claims 1
- SXTNOQAEMMAYBT-YAEBDLLGSA-N (1r,2s,5s)-3-[2-(3-acetylpyrrolo[2,3-c]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound O=C([C@@H]1[C@@H]2C[C@@H]2CN1C(=O)CN1C=C(C2=CC=NC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F SXTNOQAEMMAYBT-YAEBDLLGSA-N 0.000 claims 1
- FMKGOCAFOVIZQE-LNPFQXMTSA-N (1r,2s,5s)-3-[2-(3-acetylpyrrolo[3,2-c]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound O=C([C@@H]1[C@@H]2C[C@@H]2CN1C(=O)CN1C=C(C2=CN=CC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F FMKGOCAFOVIZQE-LNPFQXMTSA-N 0.000 claims 1
- SLJSXZAVVKCTHT-LZQZEXGQSA-N (1r,3s,5r)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CC1=NC(=C2C=CC=CN21)C(=O)C)NCC1=CC=CC(Cl)=C1F SLJSXZAVVKCTHT-LZQZEXGQSA-N 0.000 claims 1
- QESHFNIHJQIFSV-RTOPAQNCSA-N (1r,3s,5r)-2-[2-(3-acetyl-5-hydroxyindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC(O)=CC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F QESHFNIHJQIFSV-RTOPAQNCSA-N 0.000 claims 1
- IQMIWZQTGCHIHJ-LPTQZCDUSA-N (1r,3s,5r)-2-[2-(3-acetyl-6-cyanopyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=C(N=C21)C#N)C(=O)C)NCC1=CC=CC(Cl)=C1F IQMIWZQTGCHIHJ-LPTQZCDUSA-N 0.000 claims 1
- FHNOIFDKTULVDI-QPJICYPMSA-N (1r,3s,5r)-2-[2-(3-acetyl-6-hydroxyindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=C(O)C=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F FHNOIFDKTULVDI-QPJICYPMSA-N 0.000 claims 1
- DJEHGKDWMQPHEP-XRHWURSXSA-N (1r,3s,5r)-2-[2-(3-acetyl-6-phenylmethoxyindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=C(OCC=3C=CC=CC=3)C=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F DJEHGKDWMQPHEP-XRHWURSXSA-N 0.000 claims 1
- SKKPCXTZNWYSPR-OOBDGNPPSA-N (1r,3s,5r)-2-[2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(1s)-1-(3-chloro-2-fluorophenyl)-2-hydroxyethyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound C1([C@@H](CO)NC(=O)[C@@H]2C[C@H]3C[C@H]3N2C(=O)CN2C=C(C3=CC=CN=C32)C(=O)C)=CC=CC(Cl)=C1F SKKPCXTZNWYSPR-OOBDGNPPSA-N 0.000 claims 1
- HVIHNCSIZJUBRB-YSGRDPCXSA-N (1r,3s,5r)-2-[2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F HVIHNCSIZJUBRB-YSGRDPCXSA-N 0.000 claims 1
- ZOOJOYMGXHVSNF-XWIAVFTESA-N (1r,3s,5r)-2-[2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(5-chlorothiophen-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NCC1=CC=C(Cl)S1 ZOOJOYMGXHVSNF-XWIAVFTESA-N 0.000 claims 1
- LAOKGDLPBZJLJQ-YSGRDPCXSA-N (1r,3s,5r)-2-[2-(3-acetylpyrrolo[2,3-c]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=NC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F LAOKGDLPBZJLJQ-YSGRDPCXSA-N 0.000 claims 1
- XTSQWDNDTJUOKT-YSGRDPCXSA-N (1r,3s,5r)-2-[2-(3-acetylpyrrolo[3,2-b]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=NC=CC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F XTSQWDNDTJUOKT-YSGRDPCXSA-N 0.000 claims 1
- LYNXOJOQDHSCCM-LPTQZCDUSA-N (1r,3s,5r)-2-[2-(3-acetylpyrrolo[3,2-c]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CN=CC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F LYNXOJOQDHSCCM-LPTQZCDUSA-N 0.000 claims 1
- IUUOBEYNFHWBAU-LPTQZCDUSA-N (1r,3s,5r)-n-[(3-chloro-2-fluorophenyl)methyl]-2-[2-[3-(2-hydroxyacetyl)indol-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)CO)NCC1=CC=CC(Cl)=C1F IUUOBEYNFHWBAU-LPTQZCDUSA-N 0.000 claims 1
- SXTNOQAEMMAYBT-YGJVYZRNSA-N (1s,2s,5r)-3-[2-(3-acetylpyrrolo[2,3-c]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound O=C([C@@H]1[C@H]2C[C@H]2CN1C(=O)CN1C=C(C2=CC=NC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F SXTNOQAEMMAYBT-YGJVYZRNSA-N 0.000 claims 1
- MSUUVBALUUPWGY-VRUMLPLGSA-N (1s,3s,5r)-4-[2-(3-acetylindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-1-(hydroxymethyl)-4-azabicyclo[3.1.0]hexane-3-carboxamide Chemical compound O=C([C@@H]1C[C@@]2(CO)C[C@H]2N1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F MSUUVBALUUPWGY-VRUMLPLGSA-N 0.000 claims 1
- XEAZDLMCKFROGX-YUPRTTJUSA-N (1s,3s,5s)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylic acid Chemical compound OC(=O)N1[C@H](C(=O)O)C[C@@H]2C[C@@H]21 XEAZDLMCKFROGX-YUPRTTJUSA-N 0.000 claims 1
- DBQHLJOOMYBKNQ-UHFFFAOYSA-N (2,3-difluoro-4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(F)=C1F DBQHLJOOMYBKNQ-UHFFFAOYSA-N 0.000 claims 1
- MGPZOVOJXGEOTB-UHFFFAOYSA-N (2,3-difluoro-5-methoxyphenyl)methanamine Chemical compound COC1=CC(F)=C(F)C(CN)=C1 MGPZOVOJXGEOTB-UHFFFAOYSA-N 0.000 claims 1
- TYGWYXQDCGKHHY-UHFFFAOYSA-N (2,3-difluoro-6-methoxyphenyl)methanamine Chemical compound COC1=CC=C(F)C(F)=C1CN TYGWYXQDCGKHHY-UHFFFAOYSA-N 0.000 claims 1
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 claims 1
- IBDHBQSUQMLRCC-UZBSEBFBSA-N (2R,3S,4R)-4-amino-3-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound N[C@@H]1CN(C(O)=O)[C@H](C(O)=O)[C@H]1F IBDHBQSUQMLRCC-UZBSEBFBSA-N 0.000 claims 1
- HGMNTGNJUVQMAX-FQEVSTJZSA-N (2S)-1-[2-(3-formylindol-1-yl)acetyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidine-2-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(NC(=O)[C@H]2N(CCC2)C(=O)CN2C3=CC=CC=C3C(C=O)=C2)=C1 HGMNTGNJUVQMAX-FQEVSTJZSA-N 0.000 claims 1
- PJEFCTTYZPLYQI-YFKPBYRVSA-N (2S)-4,4-dimethoxypyrrolidine-1,2-dicarboxylic acid Chemical compound COC1(OC)C[C@@H](C(O)=O)N(C(O)=O)C1 PJEFCTTYZPLYQI-YFKPBYRVSA-N 0.000 claims 1
- KQDCNVVEIHHIHW-YFKPBYRVSA-N (2S)-5,5-dimethylpyrrolidine-1,2-dicarboxylic acid Chemical compound CC1(C)CC[C@@H](C(O)=O)N1C(O)=O KQDCNVVEIHHIHW-YFKPBYRVSA-N 0.000 claims 1
- HOZATCZBEQWFPV-RQJHMYQMSA-N (2S,3R)-3-(2-methoxyethylamino)pyrrolidine-1,2-dicarboxylic acid Chemical compound COCCN[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O HOZATCZBEQWFPV-RQJHMYQMSA-N 0.000 claims 1
- IDAWWRNSZMLQEK-RITPCOANSA-N (2S,3R)-3-acetamidopyrrolidine-1,2-dicarboxylic acid Chemical compound CC(=O)N[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O IDAWWRNSZMLQEK-RITPCOANSA-N 0.000 claims 1
- GLOBUKJGNIWACQ-YVZJFKFKSA-N (2S,3R,4S)-4-amino-3-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound N[C@H]1CN(C(O)=O)[C@H](C(O)=O)[C@@H]1O GLOBUKJGNIWACQ-YVZJFKFKSA-N 0.000 claims 1
- GLOBUKJGNIWACQ-UZBSEBFBSA-N (2S,3S,4R)-4-amino-3-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound N[C@@H]1CN(C(O)=O)[C@H](C(O)=O)[C@H]1O GLOBUKJGNIWACQ-UZBSEBFBSA-N 0.000 claims 1
- UIVMRMPDIKCUHI-WISUUJSJSA-N (2S,3S,4R)-4-amino-3-methoxypyrrolidine-1,2-dicarboxylic acid Chemical compound CO[C@H]1[C@H](N)CN(C(O)=O)[C@@H]1C(O)=O UIVMRMPDIKCUHI-WISUUJSJSA-N 0.000 claims 1
- UHTCLRWCFCIEDS-MHTLYPKNSA-N (2S,4R)-4-(aminomethyl)-4-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound NC[C@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 UHTCLRWCFCIEDS-MHTLYPKNSA-N 0.000 claims 1
- QMZKFOSMBYTKSY-UHNVWZDZSA-N (2S,4R)-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC[C@@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 QMZKFOSMBYTKSY-UHNVWZDZSA-N 0.000 claims 1
- RTMCNXDSXSHACI-RQJHMYQMSA-N (2S,4R)-4-[(dimethylamino)methyl]pyrrolidine-1,2-dicarboxylic acid Chemical compound CN(C)C[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 RTMCNXDSXSHACI-RQJHMYQMSA-N 0.000 claims 1
- SMEXWRPRLZNYGA-GZMMTYOYSA-N (2S,4R)-4-fluoro-4-(morpholin-4-ylmethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound C1N(C(O)=O)[C@H](C(=O)O)C[C@@]1(F)CN1CCOCC1 SMEXWRPRLZNYGA-GZMMTYOYSA-N 0.000 claims 1
- MDTRFWLINHRTJH-MHTLYPKNSA-N (2S,4R)-4-hydroxy-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC[C@@]1(O)C[C@@H](C(O)=O)N(C(O)=O)C1 MDTRFWLINHRTJH-MHTLYPKNSA-N 0.000 claims 1
- JGFYFWNELZIFMI-BQBZGAKWSA-N (2S,4S)-4-(2-methoxyethylamino)pyrrolidine-1,2-dicarboxylic acid Chemical compound COCCN[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 JGFYFWNELZIFMI-BQBZGAKWSA-N 0.000 claims 1
- IPQLKFAHUWJGQR-WHFBIAKZSA-N (2S,4S)-4-(aminomethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound NC[C@@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 IPQLKFAHUWJGQR-WHFBIAKZSA-N 0.000 claims 1
- ZOSOFKAPUSHYOU-IMJSIDKUSA-N (2S,4S)-4-(difluoromethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H](C(F)F)CN1C(O)=O ZOSOFKAPUSHYOU-IMJSIDKUSA-N 0.000 claims 1
- MFHGRSMAIMOMED-WHFBIAKZSA-N (2S,4S)-4-(methylamino)pyrrolidine-1,2-dicarboxylic acid Chemical compound CN[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 MFHGRSMAIMOMED-WHFBIAKZSA-N 0.000 claims 1
- VLITYUNEECNVNB-IMJSIDKUSA-N (2S,4S)-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H](C(F)(F)F)CN1C(O)=O VLITYUNEECNVNB-IMJSIDKUSA-N 0.000 claims 1
- IGEXCWGKQFLDKG-MHTLYPKNSA-N (2S,4S)-4-fluoro-4-(fluoromethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@@](F)(CF)CN1C(O)=O IGEXCWGKQFLDKG-MHTLYPKNSA-N 0.000 claims 1
- TUXPIGXWPLCUDJ-FFWSUHOLSA-N (2S,4S)-4-fluoro-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC[C@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 TUXPIGXWPLCUDJ-FFWSUHOLSA-N 0.000 claims 1
- NJTYCLPSZJSBSA-XNCJUZBTSA-N (2S,4S)-4-fluoro-4-(methylaminomethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound CNC[C@@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 NJTYCLPSZJSBSA-XNCJUZBTSA-N 0.000 claims 1
- SMEXWRPRLZNYGA-KWQFWETISA-N (2S,4S)-4-fluoro-4-(morpholin-4-ylmethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound C1N(C(O)=O)[C@H](C(=O)O)C[C@]1(F)CN1CCOCC1 SMEXWRPRLZNYGA-KWQFWETISA-N 0.000 claims 1
- MDTRFWLINHRTJH-FFWSUHOLSA-N (2S,4S)-4-hydroxy-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC[C@]1(O)C[C@@H](C(O)=O)N(C(O)=O)C1 MDTRFWLINHRTJH-FFWSUHOLSA-N 0.000 claims 1
- NMIGMIPMFGMJPK-RQJHMYQMSA-N (2S,5R)-5-(acetamidomethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound CC(=O)NC[C@H]1CC[C@@H](C(O)=O)N1C(O)=O NMIGMIPMFGMJPK-RQJHMYQMSA-N 0.000 claims 1
- UYSHZWDAQQYSMR-UHNVWZDZSA-N (2S,5R)-5-(aminomethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound NC[C@H]1CC[C@@H](C(O)=O)N1C(O)=O UYSHZWDAQQYSMR-UHNVWZDZSA-N 0.000 claims 1
- CVNYALMAFUPOAU-UHNVWZDZSA-N (2S,5R)-5-(azidomethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CC[C@H](CN=[N+]=[N-])N1C(O)=O CVNYALMAFUPOAU-UHNVWZDZSA-N 0.000 claims 1
- OAWXZFGKDDFTGS-SCSAIBSYSA-N (2r)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-SCSAIBSYSA-N 0.000 claims 1
- FEGUXOCIYGFNIL-ZODMCCGTSA-N (2r,3s,4r)-1-[2-(3-acetylindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-4-(dimethylamino)-3-fluoropyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H]([C@@H]1F)N(C)C)C(=O)CN1C2=CC=CC=C2C(C(C)=O)=C1)NCC1=CC=CC(Cl)=C1F FEGUXOCIYGFNIL-ZODMCCGTSA-N 0.000 claims 1
- OIUQYHJHUNOZMK-NRFANRHFSA-N (2s)-1-[2-(1-acetylindol-3-yl)acetyl]-n-[3-(trifluoromethoxy)phenyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1CCCN1C(=O)CC1=CN(C2=CC=CC=C21)C(=O)C)NC1=CC=CC(OC(F)(F)F)=C1 OIUQYHJHUNOZMK-NRFANRHFSA-N 0.000 claims 1
- MAHBOILFHNJLMT-BYPYZUCNSA-N (2s)-2,5-dihydropyrrole-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C=CCN1C(O)=O MAHBOILFHNJLMT-BYPYZUCNSA-N 0.000 claims 1
- TUGSNFQSUXFGGZ-SSDOTTSWSA-N (2s)-2-amino-2-(3-chloro-2-fluorophenyl)ethanol Chemical compound OC[C@@H](N)C1=CC=CC(Cl)=C1F TUGSNFQSUXFGGZ-SSDOTTSWSA-N 0.000 claims 1
- XPRHZDASJAMLSE-ZETCQYMHSA-N (2s)-2-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@]1(C)CCCN1C(O)=O XPRHZDASJAMLSE-ZETCQYMHSA-N 0.000 claims 1
- VLQYECILPLXQEG-QFIPXVFZSA-N (2s)-3-[2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-1,3-thiazolidine-2-carboxamide Chemical compound O=C([C@@H]1SCCN1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F VLQYECILPLXQEG-QFIPXVFZSA-N 0.000 claims 1
- ZPWSZKGQDXWSGQ-YFKPBYRVSA-N (2s)-4-methylidenepyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CC(=C)CN1C(O)=O ZPWSZKGQDXWSGQ-YFKPBYRVSA-N 0.000 claims 1
- SWVBMIRXWJHPSF-VKHMYHEASA-N (2s)-azetidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCN1C(O)=O SWVBMIRXWJHPSF-VKHMYHEASA-N 0.000 claims 1
- IEYMNLYRGAFFMR-BYPYZUCNSA-N (2s)-piperazine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CNCCN1C(O)=O IEYMNLYRGAFFMR-BYPYZUCNSA-N 0.000 claims 1
- LFEUADMCDRWDRA-UHNVWZDZSA-N (2s,3r)-3-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound C[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O LFEUADMCDRWDRA-UHNVWZDZSA-N 0.000 claims 1
- AWXDDXPSAPKTTK-IMJSIDKUSA-N (2s,3s)-3-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound O[C@H]1CCN(C(O)=O)[C@@H]1C(O)=O AWXDDXPSAPKTTK-IMJSIDKUSA-N 0.000 claims 1
- LFEUADMCDRWDRA-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound C[C@H]1CCN(C(O)=O)[C@@H]1C(O)=O LFEUADMCDRWDRA-WHFBIAKZSA-N 0.000 claims 1
- RVXAZAHGLQKESU-KSNOWIBYSA-N (2s,3s,4s)-1-[2-(3-acetyl-5-methoxyindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoro-3-methoxypyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1OC)C(=O)CN1C2=CC=C(OC)C=C2C(C(C)=O)=C1)NCC1=CC=CC(Cl)=C1F RVXAZAHGLQKESU-KSNOWIBYSA-N 0.000 claims 1
- JLXKPVSUIWXGRH-KSNOWIBYSA-N (2s,3s,4s)-1-[2-(3-acetyl-6-methoxyindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoro-3-methoxypyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1OC)C(=O)CN1C2=CC(OC)=CC=C2C(C(C)=O)=C1)NCC1=CC=CC(Cl)=C1F JLXKPVSUIWXGRH-KSNOWIBYSA-N 0.000 claims 1
- HUSYVNZGDFXVQD-QFSLSAFKSA-N (2s,3s,4s)-1-[2-(3-acetylindol-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoro-3-(trideuteriomethoxy)pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1OC([2H])([2H])[2H])C(=O)CN1C2=CC=CC=C2C(C(C)=O)=C1)NCC1=CC=CC(Cl)=C1F HUSYVNZGDFXVQD-QFSLSAFKSA-N 0.000 claims 1
- TZPGTQQECIOUOR-GVXSCFBNSA-N (2s,3s,4s)-1-[2-(3-acetylindol-1-yl)acetyl]-n-[1-(3-chlorophenyl)cyclopropyl]-4-fluoro-3-methoxypyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1OC)C(=O)CN1C2=CC=CC=C2C(C(C)=O)=C1)NC1(C=2C=C(Cl)C=CC=2)CC1 TZPGTQQECIOUOR-GVXSCFBNSA-N 0.000 claims 1
- XBPWMCZUPHMQGM-GVXSCFBNSA-N (2s,3s,4s)-1-[2-(3-acetylindol-1-yl)acetyl]-n-[1-(4-chlorophenyl)cyclopropyl]-4-fluoro-3-methoxypyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1OC)C(=O)CN1C2=CC=CC=C2C(C(C)=O)=C1)NC1(C=2C=CC(Cl)=CC=2)CC1 XBPWMCZUPHMQGM-GVXSCFBNSA-N 0.000 claims 1
- RFQDTOPGWRIDBP-YUXAGFNASA-N (2s,3s,4s)-1-[2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoro-3-methoxypyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1OC)C(=O)CN1C2=NC=CC=C2C(C(C)=O)=C1)NCC1=CC=CC(Cl)=C1F RFQDTOPGWRIDBP-YUXAGFNASA-N 0.000 claims 1
- HUSYVNZGDFXVQD-SAQHFSFASA-N (2s,3s,4s)-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoro-3-methoxy-1-[2-[3-(2,2,2-trideuterioacetyl)indol-1-yl]acetyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1[C@H](OC)[C@@H](F)CN1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)C([2H])([2H])[2H])NCC1=CC=CC(Cl)=C1F HUSYVNZGDFXVQD-SAQHFSFASA-N 0.000 claims 1
- VZQSNZRQNJJVQY-VGSWGCGISA-N (2s,4r)-1-[2-[3-acetyl-6-(hydroxymethyl)indol-1-yl]acetyl]-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoropyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CN1C=C(C2=CC=C(CO)C=C21)C(=O)C)NCC1=CC=CC(Cl)=C1F VZQSNZRQNJJVQY-VGSWGCGISA-N 0.000 claims 1
- JCINQOYGBLWVGB-WHFBIAKZSA-N (2s,4r)-4-cyanopyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@@H](C#N)CN1C(O)=O JCINQOYGBLWVGB-WHFBIAKZSA-N 0.000 claims 1
- HHDQVBSXYDRQGD-DMTCNVIQSA-N (2s,4r)-4-hydroxypyrrolidine-1,2-dicarboxylic acid Chemical compound O[C@@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 HHDQVBSXYDRQGD-DMTCNVIQSA-N 0.000 claims 1
- QLEZWYHCXVFRKO-UHNVWZDZSA-N (2s,4r)-4-methoxypyrrolidine-1,2-dicarboxylic acid Chemical compound CO[C@@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 QLEZWYHCXVFRKO-UHNVWZDZSA-N 0.000 claims 1
- VBAUXSVPMNYLSE-YADARESESA-N (2s,4r)-n-[(3-chloro-2-fluorophenyl)methyl]-4-fluoro-4-methyl-1-[2-[3-(2,2,2-trifluoroacetyl)indol-1-yl]acetyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1C[C@](CN1C(=O)CN1C2=CC=CC=C2C(C(=O)C(F)(F)F)=C1)(F)C)NCC1=CC=CC(Cl)=C1F VBAUXSVPMNYLSE-YADARESESA-N 0.000 claims 1
- QKBOXIBMPVSYAV-WDSKDSINSA-N (2s,4s)-4-(dimethylamino)pyrrolidine-1,2-dicarboxylic acid Chemical compound CN(C)[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 QKBOXIBMPVSYAV-WDSKDSINSA-N 0.000 claims 1
- GXFAYZBQUMULJS-IMJSIDKUSA-N (2s,4s)-4-fluoropyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H](F)CN1C(O)=O GXFAYZBQUMULJS-IMJSIDKUSA-N 0.000 claims 1
- UEQAUGZPSCNVMY-FFWSUHOLSA-N (2s,4s)-4-hydroxy-4-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound C[C@]1(O)C[C@@H](C(O)=O)N(C(O)=O)C1 UEQAUGZPSCNVMY-FFWSUHOLSA-N 0.000 claims 1
- QLEZWYHCXVFRKO-WHFBIAKZSA-N (2s,4s)-4-methoxypyrrolidine-1,2-dicarboxylic acid Chemical compound CO[C@H]1C[C@@H](C(O)=O)N(C(O)=O)C1 QLEZWYHCXVFRKO-WHFBIAKZSA-N 0.000 claims 1
- MVBZNUYPIUYFAK-UHNVWZDZSA-N (2s,5r)-5-(hydroxymethyl)pyrrolidine-1,2-dicarboxylic acid Chemical compound OC[C@H]1CC[C@@H](C(O)=O)N1C(O)=O MVBZNUYPIUYFAK-UHNVWZDZSA-N 0.000 claims 1
- KCRFFLRRIISICZ-ZJUUUORDSA-N (2s,5r)-5-phenylpyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)N1[C@H](C(=O)O)CC[C@@H]1C1=CC=CC=C1 KCRFFLRRIISICZ-ZJUUUORDSA-N 0.000 claims 1
- PDXRPVFVFWBERR-WHFBIAKZSA-N (2s,5s)-5-methylpyrrolidine-1,2-dicarboxylic acid Chemical compound C[C@H]1CC[C@@H](C(O)=O)N1C(O)=O PDXRPVFVFWBERR-WHFBIAKZSA-N 0.000 claims 1
- IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 claims 1
- ICIJWOWQUHHETJ-UHFFFAOYSA-N (3,5-dichlorophenyl)methanamine Chemical compound NCC1=CC(Cl)=CC(Cl)=C1 ICIJWOWQUHHETJ-UHFFFAOYSA-N 0.000 claims 1
- BAFXXIVSWGQMMI-UHFFFAOYSA-N (3-bromo-2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(Br)=C1F BAFXXIVSWGQMMI-UHFFFAOYSA-N 0.000 claims 1
- DPRZPHKUWWQDJF-ZJNRKIDTSA-N (3-chloro-2-fluorophenyl) n-[[(1r,3s,5r)-2-[(1-carbamoylindol-3-yl)carbamoyl]-2-azabicyclo[3.1.0]hexan-3-yl]methyl]carbamate Chemical compound C([C@@H]1C[C@H]2C[C@H]2N1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC(=O)OC1=CC=CC(Cl)=C1F DPRZPHKUWWQDJF-ZJNRKIDTSA-N 0.000 claims 1
- XTNITYHCBCTOTA-CKJXQJPGSA-N (3-chloro-2-fluorophenyl) n-[[(1r,3s,5r)-2-[2-(3-acetylindol-1-yl)acetyl]-2-azabicyclo[3.1.0]hexan-3-yl]methyl]carbamate Chemical compound C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)C)NC(=O)OC1=CC=CC(Cl)=C1F XTNITYHCBCTOTA-CKJXQJPGSA-N 0.000 claims 1
- LESUPVCBJDWKJH-UHFFFAOYSA-N (3-chloro-2-methylphenyl)methanamine Chemical compound CC1=C(Cl)C=CC=C1CN LESUPVCBJDWKJH-UHFFFAOYSA-N 0.000 claims 1
- MXIGALIASISPNU-UHFFFAOYSA-N (3-chloro-4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1Cl MXIGALIASISPNU-UHFFFAOYSA-N 0.000 claims 1
- BEBFJOSPYYGOKL-UHFFFAOYSA-N (3-ethylphenyl)methanamine Chemical compound CCC1=CC=CC(CN)=C1 BEBFJOSPYYGOKL-UHFFFAOYSA-N 0.000 claims 1
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 claims 1
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 claims 1
- RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 claims 1
- OWIFNISFRBVGIX-UHFFFAOYSA-N (3-phenoxyphenyl)methanamine Chemical compound NCC1=CC=CC(OC=2C=CC=CC=2)=C1 OWIFNISFRBVGIX-UHFFFAOYSA-N 0.000 claims 1
- XLBYUDUEHVKUKQ-UHFFFAOYSA-N (3-pyrrol-1-ylphenyl)methanamine Chemical compound NCC1=CC=CC(N2C=CC=C2)=C1 XLBYUDUEHVKUKQ-UHFFFAOYSA-N 0.000 claims 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 claims 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 claims 1
- XXLDTDBYQGPTNK-VKHMYHEASA-N (4r)-1,3-thiazolidine-3,4-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(O)=O XXLDTDBYQGPTNK-VKHMYHEASA-N 0.000 claims 1
- BDLPOXHSGWMLPC-BYPYZUCNSA-N (4r)-2,2-dimethyl-1,3-thiazolidine-3,4-dicarboxylic acid Chemical compound CC1(C)SC[C@@H](C(O)=O)N1C(O)=O BDLPOXHSGWMLPC-BYPYZUCNSA-N 0.000 claims 1
- WXDWGQCDPGFBEN-UHFFFAOYSA-N (5-chloro-2-methylphenyl)methanamine Chemical compound CC1=CC=C(Cl)C=C1CN WXDWGQCDPGFBEN-UHFFFAOYSA-N 0.000 claims 1
- DXYNQSROMABIPK-YFKPBYRVSA-N (6S)-5-azaspiro[2.4]heptane-5,6-dicarboxylic acid Chemical compound C1N(C(O)=O)[C@H](C(=O)O)CC11CC1 DXYNQSROMABIPK-YFKPBYRVSA-N 0.000 claims 1
- CXCIPKUYVKRZCX-UHFFFAOYSA-N 1-(3-isocyanatoindol-1-yl)ethanone Chemical compound C1=CC=C2N(C(=O)C)C=C(N=C=O)C2=C1 CXCIPKUYVKRZCX-UHFFFAOYSA-N 0.000 claims 1
- CWZUTHDJLNZLCM-DFBGVHRSSA-N 1-[2-[(1r,3s,5r)-3-[(6-bromopyridin-2-yl)carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]indazole-3-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1N=C(C2=CC=CC=C21)C(=O)N)NC1=CC=CC(Br)=N1 CWZUTHDJLNZLCM-DFBGVHRSSA-N 0.000 claims 1
- FRZMHSDOLJXJDM-DQLDELGASA-N 1-[2-[(2s,3s,4s)-3-amino-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]indole-3-carboxamide Chemical compound O=C([C@H]1N(C[C@H](F)[C@H]1N)C(=O)CN1C2=CC=CC=C2C(C(N)=O)=C1)NCC1=CC=CC(Cl)=C1F FRZMHSDOLJXJDM-DQLDELGASA-N 0.000 claims 1
- HTYCRKZEJMWWFB-YADARESESA-N 1-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoro-4-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]indole-3-carboxamide Chemical compound O=C([C@@H]1C[C@](F)(CO)CN1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F HTYCRKZEJMWWFB-YADARESESA-N 0.000 claims 1
- AAKKBRZEMWPCRL-BLVKFPJESA-N 1-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-5,6-difluoroindole-3-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CN1C=C(C2=CC(F)=C(F)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F AAKKBRZEMWPCRL-BLVKFPJESA-N 0.000 claims 1
- GQZASHFPPCKLGZ-VLIAUNLRSA-N 1-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-6-(2h-tetrazol-5-ylmethoxy)indole-3-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CN1C=C(C2=CC=C(OCC=3NN=NN=3)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F GQZASHFPPCKLGZ-VLIAUNLRSA-N 0.000 claims 1
- OQLPZWNOSYBEPG-YJYMSZOUSA-N 1-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-6-(difluoromethoxy)indole-3-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CN1C=C(C2=CC=C(OC(F)F)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F OQLPZWNOSYBEPG-YJYMSZOUSA-N 0.000 claims 1
- VMOOKOCHRUKTLT-YJYMSZOUSA-N 1-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-6-(trifluoromethoxy)indole-3-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CN1C=C(C2=CC=C(OC(F)(F)F)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F VMOOKOCHRUKTLT-YJYMSZOUSA-N 0.000 claims 1
- JTBXPPZUZWLWHN-IBGZPJMESA-N 1-[2-oxo-2-[(2s)-2-[[3-(trifluoromethoxy)phenyl]carbamoyl]pyrrolidin-1-yl]ethyl]indole-3-carboxamide Chemical compound O=C([C@@H]1CCCN1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)N)NC1=CC=CC(OC(F)(F)F)=C1 JTBXPPZUZWLWHN-IBGZPJMESA-N 0.000 claims 1
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- GUZMESBHZXQCGN-UHFFFAOYSA-N 2-(3-acetylpyrrolo[2,3-b]pyridin-1-yl)acetic acid Chemical compound C1=CC=C2C(C(=O)C)=CN(CC(O)=O)C2=N1 GUZMESBHZXQCGN-UHFFFAOYSA-N 0.000 claims 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- KPRZOPQOBJRYSW-UHFFFAOYSA-N 2-(aminomethyl)phenol Chemical compound NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 claims 1
- SJQRHEXJJFVKGH-KUHUBIRLSA-N 2-[[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]methyl]benzoic acid Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NCC1=CC=CC=C1C(O)=O SJQRHEXJJFVKGH-KUHUBIRLSA-N 0.000 claims 1
- FCZGRSXGGUAWJZ-ZMZPIMSZSA-N 2-bromo-4-[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]benzoic acid Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC1=CC=C(C(O)=O)C(Br)=C1 FCZGRSXGGUAWJZ-ZMZPIMSZSA-N 0.000 claims 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- LPEGVWXDVNTRQO-UHFFFAOYSA-N 3-(aminomethyl)-5-chloro-4-fluoro-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC(Cl)=C(F)C(CN)=C1 LPEGVWXDVNTRQO-UHFFFAOYSA-N 0.000 claims 1
- PPATWSQYYGNZDD-UHFFFAOYSA-N 3-(aminomethyl)-5-chloro-n,n-diethyl-4-fluoroaniline Chemical compound CCN(CC)C1=CC(Cl)=C(F)C(CN)=C1 PPATWSQYYGNZDD-UHFFFAOYSA-N 0.000 claims 1
- XFKPORAVEUOIRF-UHFFFAOYSA-N 3-(aminomethyl)benzonitrile Chemical compound NCC1=CC=CC(C#N)=C1 XFKPORAVEUOIRF-UHFFFAOYSA-N 0.000 claims 1
- FXPLEXVSFQOHCJ-LPTQZCDUSA-N 3-[2-[(1r,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]-2-methylindole-1-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CC1=C(N(C2=CC=CC=C21)C(N)=O)C)NCC1=CC=CC(Cl)=C1F FXPLEXVSFQOHCJ-LPTQZCDUSA-N 0.000 claims 1
- DYOVXSVHWUGKIZ-RTOPAQNCSA-N 3-[2-[(1r,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]-5-(2-hydroxyethoxy)indole-1-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CC1=CN(C2=CC=C(OCCO)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F DYOVXSVHWUGKIZ-RTOPAQNCSA-N 0.000 claims 1
- INXWTCYEKYNMTF-VEYWIMSWSA-N 3-[2-[(1r,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]-5-[2-(dimethylamino)ethoxy]indole-1-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CC1=CN(C2=CC=C(C=C21)OCCN(C)C)C(N)=O)NCC1=CC=CC(Cl)=C1F INXWTCYEKYNMTF-VEYWIMSWSA-N 0.000 claims 1
- XEJYIPYVHIOYDT-CNDZOEFASA-N 3-[2-[(1r,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]-6-(2-hydroxyethyl)indole-1-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CC1=CN(C2=CC(CCO)=CC=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F XEJYIPYVHIOYDT-CNDZOEFASA-N 0.000 claims 1
- DRBINWXQKSMLPH-XMCHAPAWSA-N 3-[2-[(1r,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CC1=CN(C2=CC=CC=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F DRBINWXQKSMLPH-XMCHAPAWSA-N 0.000 claims 1
- LKTIODJFIKBEIP-GYHJHTCASA-N 3-[2-[(1r,3s,5r)-3-[[(1r)-1-(3-chloro-2-fluorophenyl)-3-hydroxypropyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound C1([C@@H](CCO)NC(=O)[C@@H]2C[C@H]3C[C@H]3N2C(=O)CC2=CN(C3=CC=CC=C32)C(=O)N)=CC=CC(Cl)=C1F LKTIODJFIKBEIP-GYHJHTCASA-N 0.000 claims 1
- GWEUZZRZKZBCGQ-NDKINLCJSA-N 3-[2-[(1r,3s,5r)-3-[[(1s)-1-(3-chloro-2-fluorophenyl)-2-hydroxyethyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound C1([C@@H](CO)NC(=O)[C@@H]2C[C@H]3C[C@H]3N2C(=O)CC2=CN(C3=CC=CC=C32)C(=O)N)=CC=CC(Cl)=C1F GWEUZZRZKZBCGQ-NDKINLCJSA-N 0.000 claims 1
- KINAOSBOCWUKFJ-GYHJHTCASA-N 3-[2-[(1r,3s,5r)-3-[[(1s)-1-(3-chloro-2-fluorophenyl)-2-methoxyethyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound C1([C@H](NC(=O)[C@H]2N([C@@H]3C[C@@H]3C2)C(=O)CC=2C3=CC=CC=C3N(C(N)=O)C=2)COC)=CC=CC(Cl)=C1F KINAOSBOCWUKFJ-GYHJHTCASA-N 0.000 claims 1
- ZSNDJBORYCDXJP-KFSOKAEPSA-N 3-[2-[(1s,2s,5r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl]-2-oxoethyl]-5-(2-hydroxyethoxy)indole-1-carboxamide Chemical compound O=C([C@@H]1[C@H]2C[C@H]2CN1C(=O)CC1=CN(C2=CC=C(OCCO)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F ZSNDJBORYCDXJP-KFSOKAEPSA-N 0.000 claims 1
- WZLBSBJTLBBGRZ-UZINWLIJSA-N 3-[2-[(1s,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-1-(methoxymethyl)-4-azabicyclo[3.1.0]hexan-4-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound O=C([C@H]1N([C@@H]2C[C@@]2(C1)COC)C(=O)CC=1C2=CC=CC=C2N(C(N)=O)C=1)NCC1=CC=CC(Cl)=C1F WZLBSBJTLBBGRZ-UZINWLIJSA-N 0.000 claims 1
- ZUUUNVJQXYWLDH-BEFAXECRSA-N 3-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-5-fluoroindole-1-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CC1=CN(C2=CC=C(F)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F ZUUUNVJQXYWLDH-BEFAXECRSA-N 0.000 claims 1
- ZNNOECVGEINAJJ-BNIKKZEQSA-N 3-[2-[(2s,4r)-2-[[(1r)-1-(3-chloro-2-fluorophenyl)-3-hydroxypropyl]carbamoyl]-4-fluoro-4-methylpyrrolidin-1-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound C1([C@@H](CCO)NC(=O)[C@@H]2C[C@](CN2C(=O)CC=2C3=CC=CC=C3N(C(N)=O)C=2)(F)C)=CC=CC(Cl)=C1F ZNNOECVGEINAJJ-BNIKKZEQSA-N 0.000 claims 1
- IEWSPHBQZWPKIT-LVXARBLLSA-N 3-[2-[(2s,4s)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-[(dimethylamino)methyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound O=C([C@@H]1C[C@](CN1C(=O)CC=1C2=CC=CC=C2N(C(N)=O)C=1)(F)CN(C)C)NCC1=CC=CC(Cl)=C1F IEWSPHBQZWPKIT-LVXARBLLSA-N 0.000 claims 1
- OLQAHMQSIFJPBP-CYFREDJKSA-N 3-[2-[(2s,4s)-4-(aminomethyl)-2-[(3-chloro-2,6-difluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound O=C([C@@H]1C[C@](CN1C(=O)CC=1C2=CC=CC=C2N(C(N)=O)C=1)(F)CN)NCC1=C(F)C=CC(Cl)=C1F OLQAHMQSIFJPBP-CYFREDJKSA-N 0.000 claims 1
- HIEUQZOATBCTOB-UHFFFAOYSA-N 3-[2-[5-[(3-chlorophenyl)methylcarbamoyl]pyrazolidin-1-yl]-2-oxoethyl]indole-1-carboxamide Chemical compound C12=CC=CC=C2N(C(=O)N)C=C1CC(=O)N1NCCC1C(=O)NCC1=CC=CC(Cl)=C1 HIEUQZOATBCTOB-UHFFFAOYSA-N 0.000 claims 1
- DPHCCRASRWWSKR-IBGZPJMESA-N 3-[2-oxo-2-[(2s)-2-[[3-(trifluoromethoxy)phenyl]carbamoyl]pyrrolidin-1-yl]ethyl]indole-1-carboxamide Chemical compound O=C([C@@H]1CCCN1C(=O)CC1=CN(C2=CC=CC=C21)C(=O)N)NC1=CC=CC(OC(F)(F)F)=C1 DPHCCRASRWWSKR-IBGZPJMESA-N 0.000 claims 1
- WCAKBDOCTYIRJJ-HNNXBMFYSA-N 3-[[(2s)-2-[[(3-chlorophenyl)sulfonylamino]methyl]pyrrolidine-1-carbonyl]amino]indole-1-carboxamide Chemical compound C([C@@H]1CCCN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NS(=O)(=O)C1=CC=CC(Cl)=C1 WCAKBDOCTYIRJJ-HNNXBMFYSA-N 0.000 claims 1
- YKPVOMYRKFRPSB-HNNXBMFYSA-N 3-[[(2s)-2-[[3-(trifluoromethoxy)anilino]methyl]pyrrolidine-1-carbonyl]amino]indole-1-carboxamide Chemical compound C([C@@H]1CCCN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC1=CC=CC(OC(F)(F)F)=C1 YKPVOMYRKFRPSB-HNNXBMFYSA-N 0.000 claims 1
- OSQIFYVCIGRMHI-CABCVRRESA-N 3-[[(2s,4r)-4-fluoro-2-[[(3-fluorophenyl)sulfonylamino]methyl]pyrrolidine-1-carbonyl]amino]indole-1-carboxamide Chemical compound C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NS(=O)(=O)C1=CC=CC(F)=C1 OSQIFYVCIGRMHI-CABCVRRESA-N 0.000 claims 1
- ZHCIVUCBGAVRJY-ZLUZWTFRSA-N 3-[[[(1r,3s,5r)-2-[2-(3-acetylindol-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonyl]amino]methyl]-5-chloro-4-fluorobenzoic acid Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CC=C21)C(=O)C)NCC1=CC(C(O)=O)=CC(Cl)=C1F ZHCIVUCBGAVRJY-ZLUZWTFRSA-N 0.000 claims 1
- HYQOWGRLNTWQNX-ACJLOTCBSA-N 3-[[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]methyl]-5-chloro-4-fluorobenzoic acid Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NCC1=CC(C(O)=O)=CC(Cl)=C1F HYQOWGRLNTWQNX-ACJLOTCBSA-N 0.000 claims 1
- WXXRJJSXBHXJSZ-UHFFFAOYSA-N 3-aminoindole-1-carboxamide Chemical compound C1=CC=C2N(C(=O)N)C=C(N)C2=C1 WXXRJJSXBHXJSZ-UHFFFAOYSA-N 0.000 claims 1
- LZSJWUNKDMXUJY-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-3,4-dicarboxylic acid Chemical compound OC(=O)N1CC2CC1(C(O)=O)C2 LZSJWUNKDMXUJY-UHFFFAOYSA-N 0.000 claims 1
- HVRKDIITXXYLJT-SFHVURJKSA-N 3-bromo-5-[[(2s)-3-[(1-carbamoylindol-3-yl)carbamoyl]-1,3-thiazolidine-2-carbonyl]amino]benzoic acid Chemical compound O=C([C@@H]1SCCN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC1=CC(Br)=CC(C(O)=O)=C1 HVRKDIITXXYLJT-SFHVURJKSA-N 0.000 claims 1
- IBFLXEIOXGRHMX-DIFFPNOSSA-N 3-bromo-5-[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]-4-fluorobenzoic acid Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC1=CC(C(O)=O)=CC(Br)=C1F IBFLXEIOXGRHMX-DIFFPNOSSA-N 0.000 claims 1
- FFEUUKGKGSEBCI-ACJLOTCBSA-N 3-bromo-5-[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]benzoic acid Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC1=CC(Br)=CC(C(O)=O)=C1 FFEUUKGKGSEBCI-ACJLOTCBSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- DUMXYQNNRLHDOI-UHFFFAOYSA-N 3-isocyanatoindole-1-carboxamide Chemical compound C1=CC=C2N(C(=O)N)C=C(N=C=O)C2=C1 DUMXYQNNRLHDOI-UHFFFAOYSA-N 0.000 claims 1
- RQJDUEKERVZLLU-UHFFFAOYSA-N 4-Hydroxybenzylamine Chemical compound NCC1=CC=C(O)C=C1 RQJDUEKERVZLLU-UHFFFAOYSA-N 0.000 claims 1
- FJHAHFJTQYNRIX-BLVKFPJESA-N 6-bromo-1-[2-[(2s,4r)-2-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-5-fluoroindole-3-carboxamide Chemical compound O=C([C@@H]1C[C@@H](F)CN1C(=O)CN1C=C(C2=CC(F)=C(Br)C=C21)C(=O)N)NCC1=CC=CC(Cl)=C1F FJHAHFJTQYNRIX-BLVKFPJESA-N 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- HIOKSLZQCATFPU-ZVQZEWSASA-N C([C@H](N1C(O)=O)C(O)=O)[C@@]2(CO)[C@@H]1C2 Chemical compound C([C@H](N1C(O)=O)C(O)=O)[C@@]2(CO)[C@@H]1C2 HIOKSLZQCATFPU-ZVQZEWSASA-N 0.000 claims 1
- FRRYCHIRGUPULY-FJGOKHBRSA-N C1([C@@H](CCO)NC(=O)[C@@H]2C[C@H]3C[C@H]3N2C(=O)CN2C=C(C3=CC=CN=C32)C(=O)C)=CC=CC(Cl)=C1F Chemical compound C1([C@@H](CCO)NC(=O)[C@@H]2C[C@H]3C[C@H]3N2C(=O)CN2C=C(C3=CC=CN=C32)C(=O)C)=CC=CC(Cl)=C1F FRRYCHIRGUPULY-FJGOKHBRSA-N 0.000 claims 1
- VUVGOUFIDKPZKX-FJGOKHBRSA-N C1([C@H](NC(=O)[C@H]2N([C@@H]3C[C@@H]3C2)C(=O)CN2C3=CN=CC=C3C(C(C)=O)=C2)COC)=CC=CC(Cl)=C1F Chemical compound C1([C@H](NC(=O)[C@H]2N([C@@H]3C[C@@H]3C2)C(=O)CN2C3=CN=CC=C3C(C(C)=O)=C2)COC)=CC=CC(Cl)=C1F VUVGOUFIDKPZKX-FJGOKHBRSA-N 0.000 claims 1
- UBTJZEXCZPRMBJ-FJGOKHBRSA-N C1([C@H](NC(=O)[C@H]2N([C@@H]3C[C@@H]3C2)C(=O)CN2C3=NC=CC=C3C(C(C)=O)=C2)COC)=CC=CC(Cl)=C1F Chemical compound C1([C@H](NC(=O)[C@H]2N([C@@H]3C[C@@H]3C2)C(=O)CN2C3=NC=CC=C3C(C(C)=O)=C2)COC)=CC=CC(Cl)=C1F UBTJZEXCZPRMBJ-FJGOKHBRSA-N 0.000 claims 1
- QZCFBEBLJXLZTK-UHNVWZDZSA-N CO[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O Chemical compound CO[C@@H]1CCN(C(O)=O)[C@@H]1C(O)=O QZCFBEBLJXLZTK-UHNVWZDZSA-N 0.000 claims 1
- ZXSICACHUUWBKC-DEYYWGMASA-N C[C@@H](CC(C)C)NC(=O)[C@@H]1C[C@@H](CN1C(=O)NC2=CN(C3=CC=CC=C32)C(=O)N)N Chemical compound C[C@@H](CC(C)C)NC(=O)[C@@H]1C[C@@H](CN1C(=O)NC2=CN(C3=CC=CC=C32)C(=O)N)N ZXSICACHUUWBKC-DEYYWGMASA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010070476 Haemodialysis complication Diseases 0.000 claims 1
- 208000000616 Hemoptysis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 241000907681 Morpho Species 0.000 claims 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- VGJNLSVLVWSHCW-FFWSUHOLSA-N NC[C@@]1(O)C[C@@H](C(O)=O)N(C(O)=O)C1 Chemical compound NC[C@@]1(O)C[C@@H](C(O)=O)N(C(O)=O)C1 VGJNLSVLVWSHCW-FFWSUHOLSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- UVHFJFKAFOSNES-XMCHAPAWSA-N O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NC1=CC=CC(OC(F)(F)F)=C1 Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NC1=CC=CC(OC(F)(F)F)=C1 UVHFJFKAFOSNES-XMCHAPAWSA-N 0.000 claims 1
- UKVLOCVDOAMGPT-XWIAVFTESA-N O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NC1=CC=CC(OC(F)(F)F)=C1F Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C2=CC=CN=C21)C(=O)C)NC1=CC=CC(OC(F)(F)F)=C1F UKVLOCVDOAMGPT-XWIAVFTESA-N 0.000 claims 1
- LTXUFLNIXNNZAF-FZQKWOKYSA-N OC(=O)[C@@H]1C[C@H]2C[C@H]2N1C(=O)Cn1cc(C(=O)C(F)(F)F)c2ccccc12 Chemical compound OC(=O)[C@@H]1C[C@H]2C[C@H]2N1C(=O)Cn1cc(C(=O)C(F)(F)F)c2ccccc12 LTXUFLNIXNNZAF-FZQKWOKYSA-N 0.000 claims 1
- TUXPIGXWPLCUDJ-MHTLYPKNSA-N OC[C@@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 Chemical compound OC[C@@]1(F)C[C@@H](C(O)=O)N(C(O)=O)C1 TUXPIGXWPLCUDJ-MHTLYPKNSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 1
- 208000006193 Pulmonary infarction Diseases 0.000 claims 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- PQUYJDPJHOSOTN-UHFFFAOYSA-N [2-fluoro-3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1F PQUYJDPJHOSOTN-UHFFFAOYSA-N 0.000 claims 1
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 claims 1
- PRDBLLIPPDOICK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- HGHUOEJJEZTGAE-YJYMSZOUSA-N ethyl 3-bromo-5-[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]-4-fluorobenzoate Chemical compound CCOC(=O)C1=CC(Br)=C(F)C(NC(=O)[C@H]2N(C[C@H](F)C2)C(=O)NC=2C3=CC=CC=C3N(C(N)=O)C=2)=C1 HGHUOEJJEZTGAE-YJYMSZOUSA-N 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- CQILOHWHIWNQOE-UHFFFAOYSA-N indole-1-carboxamide Chemical compound C1=CC=C2N(C(=O)N)C=CC2=C1 CQILOHWHIWNQOE-UHFFFAOYSA-N 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003975 mesenteric artery Anatomy 0.000 claims 1
- KGXTYXGJQIRYEQ-JDFRZJQESA-N methyl (2s)-2-[[(2s,4s)-4-amino-1-[(1-carbamoylindol-3-yl)carbamoyl]pyrrolidine-2-carbonyl]amino]pentanoate Chemical compound CCC[C@@H](C(=O)OC)NC(=O)[C@@H]1C[C@H](N)CN1C(=O)NC1=CN(C(N)=O)C2=CC=CC=C12 KGXTYXGJQIRYEQ-JDFRZJQESA-N 0.000 claims 1
- PMEYWRODWNHWTE-SJCJKPOMSA-N methyl (3s,5s)-1-[(1-carbamoylindol-3-yl)carbamoyl]-5-[[2-fluoro-3-(trifluoromethoxy)phenyl]carbamoyl]pyrrolidine-3-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)NC=1C2=CC=CC=C2N(C(N)=O)C=1)C(=O)OC)NC1=CC=CC(OC(F)(F)F)=C1F PMEYWRODWNHWTE-SJCJKPOMSA-N 0.000 claims 1
- WTPGBDLFECAEKI-IEKZBVHVSA-N methyl 3-[[[(1r,3s,5r)-2-[2-(3-acetylindol-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonyl]amino]methyl]-5-chloro-4-fluorobenzoate Chemical compound COC(=O)C1=CC(Cl)=C(F)C(CNC(=O)[C@H]2N([C@@H]3C[C@@H]3C2)C(=O)CN2C3=CC=CC=C3C(C(C)=O)=C2)=C1 WTPGBDLFECAEKI-IEKZBVHVSA-N 0.000 claims 1
- UIANBHKOLNGHDL-KUHUBIRLSA-N methyl 3-[[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidine-2-carbonyl]amino]methyl]-5-chloro-4-fluorobenzoate Chemical compound COC(=O)C1=CC(Cl)=C(F)C(CNC(=O)[C@H]2N(C[C@H](F)C2)C(=O)NC=2C3=CC=CC=C3N(C(N)=O)C=2)=C1 UIANBHKOLNGHDL-KUHUBIRLSA-N 0.000 claims 1
- CQAPYYDHWUBSTN-HVETUWLQSA-N methyl 3-acetyl-1-[2-[(1r,3s,5r)-3-[(3-chloro-2-fluorophenyl)methylcarbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl]indole-7-carboxylate Chemical compound O=C([C@@H]1C[C@H]2C[C@H]2N1C(=O)CN1C=C(C=2C=CC=C(C1=2)C(=O)OC)C(C)=O)NCC1=CC=CC(Cl)=C1F CQAPYYDHWUBSTN-HVETUWLQSA-N 0.000 claims 1
- MRMIVRJUUNISKJ-IBGZPJMESA-N methyl 3-bromo-5-[[(2s)-3-[(1-carbamoylindol-3-yl)carbamoyl]-1,3-thiazolidine-2-carbonyl]amino]benzoate Chemical compound COC(=O)C1=CC(Br)=CC(NC(=O)[C@H]2N(CCS2)C(=O)NC=2C3=CC=CC=C3N(C(N)=O)C=2)=C1 MRMIVRJUUNISKJ-IBGZPJMESA-N 0.000 claims 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- NYCVFBXQMXSFTB-UHFFFAOYSA-N n'-[[3-(aminomethyl)-5-chloro-4-fluorophenyl]methyl]-n,n,n'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)CC1=CC(Cl)=C(F)C(CN)=C1 NYCVFBXQMXSFTB-UHFFFAOYSA-N 0.000 claims 1
- VWNZVZSGKAFOFR-UHFFFAOYSA-N n-[[3-(aminomethyl)-5-chloro-4-fluorophenyl]methyl]-2-methoxy-n-methylethanamine Chemical compound COCCN(C)CC1=CC(Cl)=C(F)C(CN)=C1 VWNZVZSGKAFOFR-UHFFFAOYSA-N 0.000 claims 1
- NWJUMMHVDMNYMJ-UHFFFAOYSA-N n-benzyl-1,1,1-trifluoromethanamine Chemical compound FC(F)(F)NCC1=CC=CC=C1 NWJUMMHVDMNYMJ-UHFFFAOYSA-N 0.000 claims 1
- HNBDRPTVWVGKBR-UHFFFAOYSA-N n-pentanoic acid methyl ester Natural products CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NWQLSIVIGQZSIA-CABCVRRESA-N phenyl n-[[(2s,4r)-1-[(1-carbamoylindol-3-yl)carbamoyl]-4-fluoropyrrolidin-2-yl]methyl]carbamate Chemical compound C([C@@H]1C[C@@H](F)CN1C(=O)NC1=CN(C2=CC=CC=C21)C(=O)N)NC(=O)OC1=CC=CC=C1 NWQLSIVIGQZSIA-CABCVRRESA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000006301 pulmonary embolism and infarction Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000017423 tissue regeneration Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161429730P | 2011-01-04 | 2011-01-04 | |
| US61/429,730 | 2011-01-04 | ||
| PCT/EP2012/050005 WO2012093101A1 (en) | 2011-01-04 | 2012-01-02 | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506877A JP2014506877A (ja) | 2014-03-20 |
| JP2014506877A5 true JP2014506877A5 (enExample) | 2015-02-19 |
| JP5921572B2 JP5921572B2 (ja) | 2016-05-24 |
Family
ID=45464587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547843A Expired - Fee Related JP5921572B2 (ja) | 2011-01-04 | 2012-01-02 | 加齢性黄斑変性症（ａｍｄ）の処置に有用なインドール化合物またはそのアナログ |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9085555B2 (enExample) |
| EP (1) | EP2661433B1 (enExample) |
| JP (1) | JP5921572B2 (enExample) |
| KR (1) | KR20140027090A (enExample) |
| CN (1) | CN103402996B (enExample) |
| AP (1) | AP2013006986A0 (enExample) |
| AR (1) | AR084768A1 (enExample) |
| AU (1) | AU2012204920B2 (enExample) |
| BR (1) | BR112013017316A2 (enExample) |
| CA (1) | CA2823665A1 (enExample) |
| CL (1) | CL2013001891A1 (enExample) |
| CO (1) | CO6791608A2 (enExample) |
| CR (1) | CR20130333A (enExample) |
| CU (1) | CU20130094A7 (enExample) |
| EA (1) | EA023259B1 (enExample) |
| ES (1) | ES2647664T3 (enExample) |
| GT (1) | GT201300174A (enExample) |
| MA (1) | MA34837B1 (enExample) |
| MX (1) | MX347391B (enExample) |
| PE (1) | PE20140471A1 (enExample) |
| PH (1) | PH12013501436A1 (enExample) |
| PL (1) | PL2661433T3 (enExample) |
| PT (1) | PT2661433T (enExample) |
| SG (1) | SG191844A1 (enExample) |
| TN (1) | TN2013000275A1 (enExample) |
| TW (1) | TW201242959A (enExample) |
| UY (1) | UY33858A (enExample) |
| WO (1) | WO2012093101A1 (enExample) |
| ZA (1) | ZA201304684B (enExample) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6155332B2 (ja) * | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| MX2014015738A (es) * | 2012-06-28 | 2015-08-06 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la senda del complemento. |
| WO2014002052A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| ES2712190T3 (es) * | 2012-06-28 | 2019-05-09 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| JP6273274B2 (ja) * | 2012-06-28 | 2018-01-31 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| JP6209605B2 (ja) * | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| WO2014002059A1 (en) * | 2012-06-29 | 2014-01-03 | Novartis Ag | CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide |
| WO2014005150A1 (en) * | 2012-06-29 | 2014-01-03 | Novartis Ag | Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof |
| EA201590200A1 (ru) * | 2012-07-12 | 2015-08-31 | Новартис Аг | Модуляторы пути активации комплемента и их применение |
| DK2878594T3 (en) * | 2012-07-27 | 2019-02-04 | Sato Pharma | DIFLUOROMETHYLENE COMPOUND |
| JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| CN104341360A (zh) * | 2013-07-31 | 2015-02-11 | 南京长澳医药科技有限公司 | 一种卢非酰胺的制备方法 |
| CN105682667A (zh) * | 2013-09-02 | 2016-06-15 | 保罗·里德 | 新的皮肤护理制剂 |
| EP3061754A4 (en) | 2013-10-23 | 2017-03-22 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2883876A1 (en) | 2013-12-16 | 2015-06-17 | Actelion Pharmaceuticals Ltd. | Stereoselective synthesis of substituted pyrrolidines |
| AP2016009438A0 (en) | 2014-02-25 | 2016-09-30 | Achillion Pharmaceuticals Inc | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
| EA038607B1 (ru) * | 2014-09-05 | 2021-09-22 | Ачиллион Фармасьютикалс, Инк. | Арильные, гетероарильные и гетероциклические соединения для лечения опосредованных комплементом расстройств |
| WO2016088082A1 (en) | 2014-12-05 | 2016-06-09 | Novartis Ag | Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof |
| WO2017035415A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035361A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035355A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035413A2 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| WO2017035348A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of medical disorders |
| EP3340983B1 (en) * | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035417A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) * | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035418A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035411A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of immune and inflammatory disorders |
| AR105808A1 (es) * | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035352A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of medical disorders |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| US20190127366A1 (en) * | 2015-12-11 | 2019-05-02 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP3394033B1 (en) | 2015-12-22 | 2020-11-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN108934169A (zh) | 2016-01-20 | 2018-12-04 | 维特里萨医疗公司 | 用于抑制因子d的组合物和方法 |
| TWI854164B (zh) | 2016-02-01 | 2024-09-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| WO2017148967A1 (en) | 2016-03-04 | 2017-09-08 | F. Hoffmann-La Roche Ag | New difluoroketamide derivatives as htra1 inhibitors |
| WO2017148964A1 (en) | 2016-03-04 | 2017-09-08 | F. Hoffmann-La Roche Ag | New trifluoromethylpropanamide derivatives as htra1 inhibitors |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
| AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20190292155A1 (en) * | 2016-07-15 | 2019-09-26 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CN109415330A (zh) | 2016-07-18 | 2019-03-01 | 豪夫迈·罗氏有限公司 | 作为htra1抑制剂的新型二氟酮酰胺衍生物 |
| CN109661389A (zh) | 2016-08-23 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 作为htra1抑制剂的新型二氟酮酰胺衍生物 |
| CN109563084A (zh) * | 2016-08-23 | 2019-04-02 | 豪夫迈·罗氏有限公司 | 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物 |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| UA125650C2 (uk) | 2016-09-09 | 2022-05-11 | Інсайт Корпорейшн | Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| GB2554071A (en) * | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| CN106588818B (zh) * | 2016-11-30 | 2019-07-26 | 兰州大学 | 一种医药中间体2,6-二氟-3-吗啉苯基甲胺及其制备方法 |
| CN108203434B (zh) * | 2016-12-20 | 2022-02-25 | 中国科学院上海药物研究所 | 一种制备索利那新的不对称合成方法 |
| MA47123A (fr) | 2016-12-22 | 2021-03-17 | Incyte Corp | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| PE20200005A1 (es) | 2016-12-22 | 2020-01-06 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1 |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| HRP20220833T1 (hr) | 2018-02-20 | 2022-10-28 | Incyte Corporation | Derivati n-(fenil)-2-(fenil)pirimidin-4-karboksamida i odgovarajući spojevi kao inhibitori hpk1 za liječenje raka |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| PL4212529T3 (pl) | 2018-03-30 | 2025-07-07 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
| CN117964683A (zh) | 2018-05-29 | 2024-05-03 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| EP3856164B1 (en) * | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| TW202028207A (zh) | 2018-09-25 | 2020-08-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| US12239645B2 (en) | 2018-12-17 | 2025-03-04 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| JP7635138B2 (ja) | 2019-03-22 | 2025-02-25 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| MX2022001562A (es) | 2019-08-06 | 2022-04-26 | Incyte Corp | Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1). |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| IL291471B2 (en) | 2019-09-30 | 2025-04-01 | Incyte Corp | Pyrimido[3,2–D]pyrimidine compounds as immunomodulators |
| CR20220237A (es) | 2019-11-11 | 2022-08-05 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| CA3159159A1 (en) * | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| WO2021113682A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US20250197403A1 (en) * | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| AR121715A1 (es) * | 2020-04-03 | 2022-06-29 | Biocryst Pharm Inc | Pirrolopirimidinaminas como inhibidores del sistema del complemento |
| BR112022022980A2 (pt) | 2020-05-12 | 2022-12-20 | Alexion Pharma Inc | Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| AR124001A1 (es) | 2020-11-06 | 2023-02-01 | Incyte Corp | Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| AU2022239717A1 (en) * | 2021-03-15 | 2023-11-02 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| CN112898273B (zh) * | 2021-03-30 | 2022-05-31 | 海南锦瑞制药有限公司 | 伏立康唑的合成方法及应用 |
| CN113372223B (zh) * | 2021-05-20 | 2022-10-28 | 宁波职业技术学院 | 一种2-氟-3-溴-苄胺的制备方法 |
| US20240360103A1 (en) * | 2021-06-30 | 2024-10-31 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| WO2023069301A1 (en) * | 2021-10-18 | 2023-04-27 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy |
| EP4174077A1 (en) * | 2021-10-27 | 2023-05-03 | Merck Patent GmbH | Electronic switching device |
| CN114105790A (zh) * | 2021-12-14 | 2022-03-01 | 无锡捷化医药科技有限公司 | 一种3-氨基-4,5-二溴苯甲酸甲酯的制备方法 |
| US20250051339A1 (en) * | 2021-12-15 | 2025-02-13 | Alexion Pharmaceuticals, Inc. | Methods for the synthesis of complement factor d inhibitors |
| AU2023238460A1 (en) * | 2022-03-25 | 2024-10-31 | Vasthera Co., Ltd. | 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient |
| WO2023200364A1 (ru) * | 2022-04-15 | 2023-10-19 | Общество С Ограниченной Ответственностью "Промомед Рус" | Способы получения (1r,2s,5s)-n-[(1s)-1-циано-2-[(3s)-2-оксопирролидин-3-ил]этил]-3-[(2s)-3,3-диметил-2-[(2,2,2-трифторацетил)амино]бутаноил]-6,6-диметил-3-азабицикло[3.1.0]гексан-2-карбоксамида |
| WO2024141011A1 (zh) * | 2022-12-31 | 2024-07-04 | 深圳晶泰科技有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
| WO2025199107A1 (en) | 2024-03-19 | 2025-09-25 | Alexion Pharmaceuticals, Inc. | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| JPH07501085A (ja) | 1992-09-03 | 1995-02-02 | ベーリンガー インゲルハイム コマンディトゲゼルシャフト | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物 |
| US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EA200001246A1 (ru) | 1998-06-03 | 2001-08-27 | Джи Пи Ай Нил Холдингс, Инк. | Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот |
| CA2334204A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Heterocyclic ester and amide hair growth compositions and uses |
| EP1083875A1 (en) | 1998-06-03 | 2001-03-21 | GPI NIL Holdings, Inc. | Small molecule carbamate or urea hair growth compositions and uses |
| US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
| US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| CA2321348A1 (en) | 2000-09-27 | 2002-03-27 | Blaise Magloire N'zemba | Aromatic derivatives with hiv integrase inhibitory properties |
| JP2004511549A (ja) | 2000-10-19 | 2004-04-15 | ナエジャ ファーマシューティカル インク | システインプロテアーゼ阻害剤としての新規のジヒドロピリミジン誘導体 |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| TWI317634B (en) | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
| NL1021590C1 (nl) | 2002-10-05 | 2004-04-06 | Johannes Antonius Josep Visser | Oogstinrichting voor het oogsten van gewassen en sorteerinrichting. |
| EP1581503A4 (en) | 2002-11-08 | 2007-07-25 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| SG2012000667A (en) | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| WO2004062607A2 (en) | 2003-01-13 | 2004-07-29 | Ying Zhang | Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| DE502004009440D1 (de) | 2003-04-03 | 2009-06-10 | Merck Patent Gmbh | Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen |
| US7959919B2 (en) | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
| EP1713503B1 (en) | 2004-02-10 | 2013-07-31 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor b, the alternative complement pathway and methods related thereto |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| DE102004045796A1 (de) | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
| FR2876692B1 (fr) | 2004-10-19 | 2007-02-23 | Sanofi Aventis Sa | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
| EP1856102B1 (en) | 2005-02-28 | 2009-06-17 | Tseti, Ioulia | Medicaments for alzheimer |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2609203A1 (en) | 2005-05-23 | 2006-11-30 | Merck & Co., Inc | Proline bis-amide orexin receptor antagonists |
| US20070105781A1 (en) | 2005-08-02 | 2007-05-10 | Steve Lyons | Inhibitors of serine proteases |
| JP5345849B2 (ja) | 2005-10-08 | 2013-11-20 | ポテンシア ファーマシューティカルズ， インコーポレイテッド | 眼の障害のためのコンプスタチンおよびそのアナログ |
| TW200730476A (en) | 2005-12-12 | 2007-08-16 | Genelabs Tech Inc | N-(5-membered aromatic ring)-amido anti-viral compounds |
| HUE026496T2 (en) | 2006-03-08 | 2016-06-28 | Archemix Llc | Complement-binding aptamers and anti-C5 agents for treating eye diseases |
| SI2049478T1 (sl) * | 2006-07-06 | 2012-08-31 | Glaxo Group Ltd | Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo |
| WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
| CN106084054A (zh) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| EP2099778A2 (en) | 2006-11-21 | 2009-09-16 | Smithkline Beecham Corporation | Amido anti-viral compounds |
| EP1988098A1 (en) | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| ES2522346T3 (es) * | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2012
- 2012-01-02 WO PCT/EP2012/050005 patent/WO2012093101A1/en not_active Ceased
- 2012-01-02 JP JP2013547843A patent/JP5921572B2/ja not_active Expired - Fee Related
- 2012-01-02 MX MX2013007867A patent/MX347391B/es active IP Right Grant
- 2012-01-02 AU AU2012204920A patent/AU2012204920B2/en not_active Ceased
- 2012-01-02 PL PL12700094T patent/PL2661433T3/pl unknown
- 2012-01-02 ES ES12700094.1T patent/ES2647664T3/es active Active
- 2012-01-02 EA EA201391000A patent/EA023259B1/ru not_active IP Right Cessation
- 2012-01-02 PT PT127000941T patent/PT2661433T/pt unknown
- 2012-01-02 KR KR1020137020527A patent/KR20140027090A/ko not_active Ceased
- 2012-01-02 PE PE2013001512A patent/PE20140471A1/es not_active Application Discontinuation
- 2012-01-02 PH PH1/2013/501436A patent/PH12013501436A1/en unknown
- 2012-01-02 SG SG2013051669A patent/SG191844A1/en unknown
- 2012-01-02 AP AP2013006986A patent/AP2013006986A0/xx unknown
- 2012-01-02 BR BR112013017316A patent/BR112013017316A2/pt not_active IP Right Cessation
- 2012-01-02 MA MA36128A patent/MA34837B1/fr unknown
- 2012-01-02 CA CA2823665A patent/CA2823665A1/en not_active Abandoned
- 2012-01-02 CN CN201280011428.5A patent/CN103402996B/zh not_active Expired - Fee Related
- 2012-01-02 US US13/342,161 patent/US9085555B2/en active Active
- 2012-01-02 EP EP12700094.1A patent/EP2661433B1/en not_active Not-in-force
- 2012-01-03 TW TW101100198A patent/TW201242959A/zh unknown
- 2012-01-03 UY UY0001033858A patent/UY33858A/es not_active Application Discontinuation
- 2012-01-03 AR ARP120100007A patent/AR084768A1/es unknown
-
2013
- 2013-06-24 ZA ZA2013/04684A patent/ZA201304684B/en unknown
- 2013-06-26 TN TNP2013000275A patent/TN2013000275A1/fr unknown
- 2013-06-26 CL CL2013001891A patent/CL2013001891A1/es unknown
- 2013-07-02 CR CR20130333A patent/CR20130333A/es unknown
- 2013-07-02 GT GT201300174A patent/GT201300174A/es unknown
- 2013-07-02 CU CU2013000094A patent/CU20130094A7/es unknown
- 2013-07-02 CO CO13155727A patent/CO6791608A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506877A5 (enExample) | ||
| CN107922392B (zh) | 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途 | |
| JP2025016684A5 (enExample) | ||
| RU2484091C2 (ru) | Производные изоксазоло-пиридина | |
| JP2023087046A (ja) | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 | |
| JP5921572B2 (ja) | 加齢性黄斑変性症（ａｍｄ）の処置に有用なインドール化合物またはそのアナログ | |
| CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
| JP2019525941A5 (enExample) | ||
| JPWO2021055744A5 (enExample) | ||
| EA032609B1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| JP2011500806A5 (enExample) | ||
| JP2010508338A5 (enExample) | ||
| RU2016112952A (ru) | Производные индола и индазола | |
| JP2016505557A5 (enExample) | ||
| JP2010513379A5 (enExample) | ||
| HRP20250104T1 (hr) | Novi supstituirani derivati sulfonilureje | |
| AU2004309254A1 (en) | Amidopyrazole derivative | |
| JP2024009891A (ja) | Ｔ型カルシウムチャネル阻害剤 | |
| CN102686564B (zh) | 吡咯烷衍生物 | |
| JP2022081710A (ja) | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 | |
| JP2014528462A (ja) | ２−オキソ−ピペリジニル誘導体 | |
| AU2010215513B2 (en) | Pyrrolidine derivatives as NK3 receptor antagonists | |
| JPWO2020203609A5 (enExample) | ||
| CN113563245A (zh) | 取代的吡咯烷类化合物及其在药物中的应用 |